JP2002525274A - 成長ホルモン分泌促進剤による独立生活状況への復帰促進 - Google Patents

成長ホルモン分泌促進剤による独立生活状況への復帰促進

Info

Publication number
JP2002525274A
JP2002525274A JP2000571019A JP2000571019A JP2002525274A JP 2002525274 A JP2002525274 A JP 2002525274A JP 2000571019 A JP2000571019 A JP 2000571019A JP 2000571019 A JP2000571019 A JP 2000571019A JP 2002525274 A JP2002525274 A JP 2002525274A
Authority
JP
Japan
Prior art keywords
alkyl
growth hormone
aryl
carbonyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000571019A
Other languages
English (en)
Japanese (ja)
Inventor
バツク,マーク
フユー,ビビアン
ウー,ジエニフアー
テイラー,アリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9823090.7A external-priority patent/GB9823090D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2002525274A publication Critical patent/JP2002525274A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4747Quinolines; Isoquinolines spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2000571019A 1998-09-02 1999-08-31 成長ホルモン分泌促進剤による独立生活状況への復帰促進 Withdrawn JP2002525274A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9886998P 1998-09-02 1998-09-02
GB60/098,869 1998-10-21
GBGB9823090.7A GB9823090D0 (en) 1998-10-21 1998-10-21 Enhancement of return to independent living status with a growth hormone secretaogue
GB9823090.7 1998-10-21
PCT/US1999/019996 WO2000012047A2 (en) 1998-09-02 1999-08-31 Enhancement of return to independent living status with a growth hormone secretagogue

Publications (1)

Publication Number Publication Date
JP2002525274A true JP2002525274A (ja) 2002-08-13

Family

ID=26314549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000571019A Withdrawn JP2002525274A (ja) 1998-09-02 1999-08-31 成長ホルモン分泌促進剤による独立生活状況への復帰促進

Country Status (5)

Country Link
EP (1) EP1156808A2 (de)
JP (1) JP2002525274A (de)
AU (1) AU6133299A (de)
CA (1) CA2341649A1 (de)
WO (1) WO2000012047A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530309A (ja) * 2006-03-15 2009-08-27 マイケル・オー・ソーナー 成長ホルモン分泌促進物質による筋肉減少症の処置方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
EP1192943A3 (de) * 2000-09-28 2002-11-27 Pfizer Products Inc. Verwendung von Sekretionsfördermitteln für Wachstumshormone in Verbindung mit Körpertraining
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
US7396846B2 (en) 2002-04-09 2008-07-08 Eli Lilly And Company Growth hormone secretagogues
WO2005097174A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of a combination of ghrelin and somatotropin for the treatment of cachexia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6772996A (en) * 1995-08-21 1997-03-12 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
US5723616A (en) * 1995-10-27 1998-03-03 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
US5767124A (en) * 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
CA2240427C (en) * 1995-12-13 2007-08-14 Merck & Co., Inc. Growth hormone secretagogue receptor family
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530309A (ja) * 2006-03-15 2009-08-27 マイケル・オー・ソーナー 成長ホルモン分泌促進物質による筋肉減少症の処置方法
JP2013151524A (ja) * 2006-03-15 2013-08-08 Michael O Thorner 成長ホルモン分泌促進物質による筋肉減少症の処置方法

Also Published As

Publication number Publication date
EP1156808A2 (de) 2001-11-28
WO2000012047A3 (en) 2001-09-27
AU6133299A (en) 2000-03-21
WO2000012047A2 (en) 2000-03-09
CA2341649A1 (en) 2000-03-09

Similar Documents

Publication Publication Date Title
US9468639B2 (en) Treating sexual desire disorders with flibanserin
EP1159964B1 (de) Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
KR101718639B1 (ko) 선별적 s1p₁ 수용체 작동약에 대한 투약 섭생
WO1997041878A1 (en) Treatment of mood disorders with a growth hormone secretagogue
RU2324484C2 (ru) Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты)
JP2000511885A (ja) 成長ホルモン分泌促進薬による睡眠の強化
US6194402B1 (en) Enhancement of return to independent living status with a growth hormone secretagogue
JPH0812575A (ja) 口腔乾燥症治療剤
US20020013320A1 (en) Use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
JP2002525274A (ja) 成長ホルモン分泌促進剤による独立生活状況への復帰促進
CA2351897A1 (en) Use of growth hormone secretagogues for treatment of physical performance decline
EP1082118B1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
US20120122919A1 (en) Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist
US20020002137A1 (en) Combination of growth hormone secretagogues and antidepressants
KR20020025730A (ko) 운동과 병행한, 성장 호르몬 분비촉진제의 용도
JP2002293743A (ja) 食欲を刺激するかまたは増進させるための成長ホルモン分泌促進物質の使用
JPH08507514A (ja) 脳血管性疾患を治療または予防するための薬物
JPS61280430A (ja) 抗乳汁分泌活性を有する医薬組成物
EP1611901A1 (de) Mittel zur prävention oder heilung von zähneknirschen
US20030207891A1 (en) Combination therapy for modulating the human sexual response
JPH0827029A (ja) 5ht1 作動薬の新規医薬用途
WO1993018769A2 (en) A new use of quinazoline derivative
JP2002114681A (ja) 勃起不全治療剤

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20061107